According to the latest reports, there are nearly 200 hospitals in China providing CAR T-cell therapy for the treatment of lymphoma.

Chimeric antigen receptor (CAR) T-cell therapy is a breakthrough immunotherapy approved in China for the treatment of lymphoma, and application of approval in treating for relapsed or refractory multiple myeloma is currently under China’s National Medical Products Administration’s review.

There are two commercial CAR T-cell therapy products available in China at the moment:

Yescarta (axicabtagene ciloleucel), the first commercial CAR T-cell therapy in China was approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, including:

Carteyva (relmacabtagene autoleucel, relma-cel), the second commercial CAR T-cell therapy in China, developed based on Junos’  JCAR017, was approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (DLBCL) after second-line or more systemic therapy, including: